Subscribe
Home
Issues
Online First
2024
February 2024 - Vol 17 No 1
2023
December 2023 - Vol 16 No 6
October 2023 - Vol 16 No 5
August 2023 - Vol 16 No 4
June 2023 - Vol 16 No 3
April 2023 - Vol 16 No 2
February 2023 - Vol 16 No 1
Issue Archive
Special Issues
Supplements
Guide to New FDA Approvals
Categories
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
ONS 2023 - Multiple Myeloma: Wrap-Up
Web Exclusives
OFS Summit
Interview with the Innovators
Drug Updates
Media Library
Videos
Rapid Reactions
Audiocasts
Ask the Experts
Master Class Series
Resources
Quick Quiz
CE
Genetic Counseling
New Data Suggest Clinicians Should Consider Genetic Counseling and BRCA1/2 Testing for Any Patient with Pancreatic Adenocarcinoma
By
Cristi Radford, MS, CGC
Genetic Counseling
TON July 2015 Vol 8 No 4
Pancreatic cancer represents 3% of new cancer cases each year, with the average age of diagnosis being 71 years.
Read More ›
Inherited Ovarian Cancer: What Have We Learned?
By
Cristi Radford, MS, CGC
Genetic Counseling
TON May 2015 Vol 8 No 3
Due to the high mortality rate and lack of effective surveillance methods, identifying women at increased risk for ovarian cancer is crucial for offering risk-reducing procedures.
Read More ›
Expanding Phenotypes of Inherited Colorectal Cancer Syndromes
By
Cristi Radford, MS, CGC
Genetic Counseling
TON - November/December 2014 Vol 7 No 6
The first multigene panels for colorectal cancer became clinically available in 2012. Prior to that date, clinical testing for inherited colorectal cancer syndromes typically proceeded in a sequential fashion. A clinician would develop a differential diagnosis and test corresponding genes in order of those most likely to have a causative mutation. Thus, analyzing multiple genes for inherited colorectal cancer risk was both time intensive and costly.
Read More ›
What Is PALB2?
By
Tuya Pal, MD, FABMG
;
Cristi Radford, MS, CGC
Genetic Counseling
TON - September/October 2014 Vol 7 No 5
ou may have heard about this gene on the radio or in a news article lately. What’s all the fuss about? On August 7, 2014, the
New England Journal of Medicine (NEJM)
published an article discussing breast cancer risk in families with mutations in
PALB2
.
Read More ›
What Is “Next-Gen?”
By
Cristi Radford, MS, CGC
Genetic Counseling
TON - July/August 2014 Vol 7 No 4
In this month’s issue of The Oncology Nurse-APN/PA (TON), we continue our coverage of the news from the recent Oncology Nursing Society (ONS) 39th Annual Congress and the 2014 Annual Meeting of the American Society of Clinical Oncology (ASCO).
Read More ›
Hereditary Melanoma
By
Cristi Radford, MS, CGC
Genetic Counseling
TON - March/April 2014 Vol 7 No 2
May 5th is Melanoma Monday, as designated by the American Academy of Dermatology.
Read More ›
Reproductive Options for Hereditary Cancer Syndromes
By
Cristi Radford, MS, CGC
Genetic Counseling
TON - January/February 2014 Vol 7 No 1
The majority of hereditary cancer syndromes are inherited in an autosomal dominant fashion. Thus, offspring have a 50% chance of inheriting the condition, as well as a 50% chance of not inheriting it.
Read More ›
Inherited Susceptibility to Lung Cancer: What Do We Know?
By
Cristi Radford, MS, CGC
Genetic Counseling
TON - November 2013 Vol 6 No 10
In 2013 it is estimated that there will be 228,190 new cases and 159,480 deaths due to lung cancer in the United States, making it the leading cause of cancer-related death.
Read More ›
Genetic Testing for BRCA1/2
By
Angela Long
;
Cristi Radford, MS, CGC
Genetic Counseling
TON - August 2013 Vol 6 No 7
The announcement this spring by Angelina Jolie that she had undergone a risk-reducing double mastectomy after learning she carried a mutation in the BRCA1 gene, as well as the recent US Supreme Court decision on gene patenting, has resulted in an influx of questions to both genetic providers and support organizations about hereditary breast cancer.
Read More ›
Genetic Susceptibility to Renal Cell Carcinoma
By
Cristi Radford, MS, CGC
Genetic Counseling
TON - June 2013, Vol 6, No 5
In 2013, approximately 65,000 people will be diagnosed with kidney cancer and two-thirds will be men.
Read More ›
Page 3 of 5
1
2
3
4
5
View the Latest Issue of TON
Read Issue
Home
Issues
Online First
2024
February 2024 - Vol 17 No 1
2023
December 2023 - Vol 16 No 6
October 2023 - Vol 16 No 5
August 2023 - Vol 16 No 4
June 2023 - Vol 16 No 3
April 2023 - Vol 16 No 2
February 2023 - Vol 16 No 1
Issue Archive
Special Issues
Supplements
Guide to New FDA Approvals
Categories
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
ONS 2023 - Multiple Myeloma: Wrap-Up
Web Exclusives
OFS Summit
Interview with the Innovators
Drug Updates
Media Library
Videos
Rapid Reactions
Audiocasts
Ask the Experts
Master Class Series
Resources
Quick Quiz
CE
Subscribe Today!
To sign up for our newsletter or print publications, please enter your contact information below.
I'd like to receive:
TON
Print Edition
TON
Weekly e‑Newsletter
-- Please Select --
Afghanistan
Åland Islands
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antarctica
Antigua and Barbuda
Argentina
Armenia
Aruba
Australia
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia, Plurinational State of
Bonaire, Sint Eustatius and Saba
Bosnia and Herzegovina
Botswana
Bouvet Island
Brazil
British Indian Ocean Territory
Brunei Darussalam
Bulgaria
Burkina Faso
Burundi
Cambodia
Cameroon
Canada
Cape Verde
Cayman Islands
Central African Republic
Chad
Chile
China
Christmas Island
Cocos (Keeling) Islands
Colombia
Comoros
Congo
Congo, the Democratic Republic of the
Cook Islands
Costa Rica
Côte d'Ivoire
Croatia
Cuba
Curaçao
Cyprus
Czech Republic
Denmark
Djibouti
Dominica
Dominican Republic
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Falkland Islands (Malvinas)
Faroe Islands
Fiji
Finland
France
French Guiana
French Polynesia
French Southern Territories
Gabon
Gambia
Georgia
Germany
Ghana
Gibraltar
Greece
Greenland
Grenada
Guadeloupe
Guam
Guatemala
Guernsey
Guinea
Guinea-Bissau
Guyana
Haiti
Heard Island and McDonald Islands
Holy See (Vatican City State)
Honduras
Hong Kong
Hungary
Iceland
India
Indonesia
Iran, Islamic Republic of
Iraq
Ireland
Isle of Man
Israel
Italy
Jamaica
Japan
Jersey
Jordan
Kazakhstan
Kenya
Kiribati
Korea, Democratic People's Republic of
Korea, Republic of
Kuwait
Kyrgyzstan
Lao People's Democratic Republic
Latvia
Lebanon
Lesotho
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Macao
Macedonia, the former Yugoslav Republic of
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Martinique
Mauritania
Mauritius
Mayotte
Mexico
Micronesia, Federated States of
Moldova, Republic of
Monaco
Mongolia
Montenegro
Montserrat
Morocco
Mozambique
Myanmar
Namibia
Nauru
Nepal
Netherlands
New Caledonia
New Zealand
Nicaragua
Niger
Nigeria
Niue
Norfolk Island
Northern Mariana Islands
Norway
Oman
Pakistan
Palau
Palestinian Territory, Occupied
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Pitcairn
Poland
Portugal
Puerto Rico
Qatar
Réunion
Romania
Russian Federation
Rwanda
Saint Barthélemy
Saint Helena, Ascension and Tristan da Cunha
Saint Kitts and Nevis
Saint Lucia
Saint Martin (French part)
Saint Pierre and Miquelon
Saint Vincent and the Grenadines
Samoa
San Marino
Sao Tome and Principe
Saudi Arabia
Senegal
Serbia
Seychelles
Sierra Leone
Singapore
Sint Maarten (Dutch part)
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
South Georgia and the South Sandwich Islands
South Sudan
Spain
Sri Lanka
Sudan
Suriname
Svalbard and Jan Mayen
Swaziland
Sweden
Switzerland
Syrian Arab Republic
Taiwan, Province of China
Tajikistan
Tanzania, United Republic of
Thailand
Timor-Leste
Togo
Tokelau
Tonga
Trinidad and Tobago
Tunisia
Turkey
Turkmenistan
Turks and Caicos Islands
Tuvalu
Uganda
Ukraine
United Arab Emirates
United Kingdom
United States
United States Minor Outlying Islands
Uruguay
Uzbekistan
Vanuatu
Venezuela, Bolivarian Republic of
Viet Nam
Virgin Islands, British
Virgin Islands, U.S.
Wallis and Futuna
Western Sahara
Yemen
Zambia
Zimbabwe
I have reviewed and consent to the terms of
TON
's
Privacy Policy
, and
TON
has my permission to retain my information in its database, and to forward pertinent communications to me.
START YOUR SUBSCRIPTION